Detalhe da pesquisa
1.
Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.
Haematologica
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235519
2.
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study.
Haematologica
; 2024 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38841794
3.
Efficacy of natural killer cell therapy combined with chemoradiotherapy in murine models of head and neck squamous cell carcinoma.
Cytotherapy
; 26(3): 242-251, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38142382
4.
Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis.
Ann Hematol
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38267559
5.
The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR).
BMC Med Res Methodol
; 24(1): 102, 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38698331
6.
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model.
Cancer Immunol Immunother
; 72(5): 1233-1246, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36385211
7.
Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).
Ann Hematol
; 102(8): 2233-2240, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37392367
8.
Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21.
Cancer Immunol Immunother
; 71(3): 613-625, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34282497
9.
Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer.
Cytotherapy
; 24(9): 905-915, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35778350
10.
Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.
Ann Hematol
; 101(6): 1217-1226, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35445844
11.
Diagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma.
J Korean Med Sci
; 37(1): e2, 2022 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981678
12.
Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy.
Br J Haematol
; 193(1): 101-112, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33368165
13.
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Cancer Immunol Immunother
; 70(1): 31-45, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32623477
14.
Safety and immunological effects of recombinant canine IL-15 in dogs.
Cytokine
; 148: 155599, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34103211
15.
Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
Ann Hematol
; 100(8): 2051-2059, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33447888
16.
Pilot Study: Quantitative Photoacoustic Evaluation of Peripheral Vascular Dynamics Induced by Carfilzomib In Vivo.
Sensors (Basel)
; 21(3)2021 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33513784
17.
Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse.
Blood
; 132(15): 1604-1613, 2018 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30108064
18.
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.
Blood
; 131(3): 301-310, 2018 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29150421
19.
Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma.
BMC Cancer
; 20(1): 803, 2020 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32831058
20.
HMGB1 modulates the balance between senescence and apoptosis in response to genotoxic stress.
FASEB J
; 33(10): 10942-10953, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31284735